Press release

Cinclus Pharma's data presented at UEG

The results of a phase 1 study of the acid inhibition effect of Cinclus Pharma's P-CAB linaprazan glurate will be presented at the leading congress United European Gastroenterology Week (UEG) 12 – 15 October 2024. The study results show that linaprazan glurate has a very rapid and effective acid inhibition already 90 minutes after first dosing. The best doses provide near complete acid control (pH>4) over all 24 hours of the day.

"Since only leading and new research is selected by the UEG, we are incredibly proud that our data is presented. It indicates that our P-CAB linaprazan glurate is very interesting for gastroenterology. The data we present provide very good conditions to heal all patients suffering from eGERD, including the most difficult patients who are also our primary target group. We are moving forward with the goal of bringing about a paradigm shift in the treatment of gastric acid related diseases," said Christer Ahlberg, CEO of Cinclus Pharma.

The abstract Pharmacokinetics and pharmacodynamics of Linaprazan glurate after multiple oral doses up to 14 days in healthy subjects is presented on Sunday, October 13, 16:18 - 16:30.

About linaprazan glurate
Linaprazan glurate has been developed by Cinclus Pharma and is a prodrug of the P-CAB linaprazan, the main and active metabolite, originally developed by AstraZeneca. Linaprazan and linaprazan glurate have been evaluated in more than 30 phase I and two phase II studies, exposing over 3,000 individuals to linaprazan or linaprazan glurate. Linaprazan glurate is being developed for the treatment of severe gastroesophageal reflux disease (GERD). Linaprazan glurate has the potential to heal erosions in the esophageal mucosa caused by leaked stomach acid and to alleviate GERD symptoms more effectively and rapidly than current pharmaceutical treatments, including proton pump inhibitors (PPI). The favorable safety, efficacy, and pharmacokinetic properties of linaprazan glurate have been documented in several phase I and one phase II study. Planning for the initiation of the phase III program is underway, with an expected study start in 2025.

About GERD
Gastroesophageal reflux disease (GERD) is a digestive disorder that affects the lower esophageal sphincter (LES), the ring of muscle between the esophagus and the stomach, causing a backflow of stomach contents into the esophagus. This leads to erosions, acid reflux, and heartburn caused by stomach acid. Approximately 133 million adults in the US and EU-30 suffer from GERD. The global market for acid reflux is dominated by proton pump inhibitors (PPI). To heal the most vulnerable patients with the most severe erosions, acid control must be maintained around the clock. Overall, about 10 million patients in the EU and the US suffer from the most severe form of eGERD. Many of these are not helped by the current standard treatment, indicating a clear need for better medications to treat GERD. Linaprazan glurate is developed to meet these patients' needs.

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a clinical late stage pharma company developing a small molecule for the treatment of gastric acid-related diseases and disorders of the upper gastrointestinal tract. Its drug candidate linaprazan glurate represents a novel class of drugs, Potassium-Competitive Acid Blockers (P‑CAB), and provides a fast-acting control of intragastric pH by a different mechanism of action than proton pump inhibitors (PPIs), with unique capacity to deliver acid control, pH>4, around the clock. For more information, please visit www.cincluspharma.com.